OpenResearchAlpha

JCO Precision Oncology · 13 Nov 2026

Impact of Clonal Hematopoiesis on Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma: Analysis From the PASS-01 Trial

Panot Sainamthiph-index 3, Meenakshi Somadasan, Leigh Culnane, Elizabeth Andrews, Lauren Brais, Molly Andrews, Gun Ho Jang, Amy Zhang, Julie M. Wilson, Stephanie Ramotar, Anna Dodd, Kimberly J. Perez, Kenneth Yu, Daniel Laheru, Daniel A. King, Grainne M. O'Kane, Steven Gallinger, David Tuveson, Elizabeth M. Jaffee, Jennifer J. Knox, Faiyaz Notta, Andrew J. Aguirre, Brian M. Wolpin, Adam S. Sperling, Harshabad Singhh-index 13

0
Citations
no database records one yet
0
Citations in 2026
so far
13
Leading author's h-index
Harshabad Singh, in QAI's scholar index
19
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Purpose Clonal hematopoiesis (CH) is increasingly recognized as a proinflammatory driver of adverse outcomes in solid tumors. Tumor-infiltrating immune cells with CH (TI-CH) actively promote tumor growth and those harboring TI-CH experience significantly worse survival. We investigated the prevalence and impact of CH on outcomes in patients with treatment-naïve metastatic pancreatic ductal adenocarcinoma (PDAC). Methods Peripheral blood from 125 patients with metastatic PDAC enrolled in the PASS-01 trial (ClinicalTrials.gov identifier: NCT04469556 ) was evaluated. CH was defined as the presence of pathogenic or likely pathogenic variants with a variant allele frequency (VAF) of ≥1% in a 23 gene panel. Survival was estimated using the Kaplan-Meier method and compared using the log-rank test. Hazard ratios (HRs) were estimated using multivariable Cox proportional hazards regression. Results CH was detected in 36.8% (46 of 125) of patients, and DNMT3A (60.9%) and TET2 (17.4%) were the most frequently mutated genes. There was no significant difference in progression-free survival (PFS; median, 4.9 v 5.2 months; HR, 1.01 [95% CI, 0.68 to 1.49]; P = .95) and overall survival (OS; median, 9.4 v 9.6 months; HR, 0.99 [95% CI, 0.63 to 1.53]; P = .95) between CH-positive and CH-negative patients, respectively. Among patients with basal-like subtype (n = 23), the presence of CH was associated with a numerically shorter PFS (median, 2.4 v 4.7 months; HR, 2.50 [95% CI, 0.93 to 6.84]; P = .06) and OS (median, 6.2 v 10.2 months; HR, 1.37 [95% CI, 0.51 to 3.69]; P = .52). In contrast, classical subtype showed no significant differences in survival outcomes by CH. Conclusion CH is prevalent in metastatic PDAC but not independently prognostic. Further examination of CH in basal subtype tumors and the role of TI-CH in PDAC is needed.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Harshabad Singh has the highest h-index among the authors (13).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (25)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (19)

What it cites, from open citation data, with Crossref's record of each.

Impact of Clonal Hematopoiesis on Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma: Analysis From the PASS-01 Trial - QAI OpenResearch